NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

非癌症領域精密醫學的全球市場(2020-2030):按應用,生態系統和地區劃分

Global Non-Oncology Precision Medicine Market: Focus on Application Area, Ecosystem Type, Country Data (15 Countries) - Analysis and Forecast, 2020-2030

出版商 BIS Research Inc. 商品編碼 966586
出版日期 內容資訊 英文 306 Pages
商品交期: 最快1-2個工作天內
價格
非癌症領域精密醫學的全球市場(2020-2030):按應用,生態系統和地區劃分 Global Non-Oncology Precision Medicine Market: Focus on Application Area, Ecosystem Type, Country Data (15 Countries) - Analysis and Forecast, 2020-2030
出版日期: 2020年10月15日內容資訊: 英文 306 Pages
簡介

在預測期內,全球非癌精密醫療市場預計將保持11.03%的複合年增長率,從2019年的411億美元增長到2030年的1299.6億美元。公眾對分子水平的診斷和治療的意識增強以及政府各種舉措的增多等因素正在推動市場的增長。諸如分子診斷學的進步,對公司對開發新的個性化藥物的投資的興趣日益增加以及FDA批准的藥物的增加等因素也有望推動進一步的發展。

本報告探討了全球非癌症精密醫療市場,定義和概述了市場,分析了新型冠狀病毒感染(COVID-19)和其他市場影響因素以及監管框架。技術/專利趨勢,市場規模趨勢/預測,使用情況/生態系統/區域/主要國家/地區細分(按類別,競爭環境,主要公司的概況等)

執行摘要

第1章產品定義

第2章調查範圍

第3章調查方法

第4章市場概述

  • 簡介
  • 以預防為重點的實現精確醫療的技術
  • 精準醫學的前景和重要性

第5章COVID-19的影響

第6章工業分析

  • 法律法規框架/要求
  • 專利狀況

第7章市場動態

  • 概述
  • 市場增長推進因子
  • 市場增長抑制因子
  • 市場機會

第8章競爭情況

  • 主要策略和發展
  • 市場佔有率分析
  • 增長/佔有率分析:按公司劃分

第9章市場分析/預測:按應用

  • 概述
  • 傳染病
    • 呼吸道感染
    • 胃腸道感染
    • 性感染
    • 其他
  • 神經/物理療法
    • 神經退行性疾□□病
    • 神經精神疾病
    • 其他
  • 生活方式疾病/內分泌系統
  • 心血管
    • 心肌肌病/心律不齊
    • 其他
  • 腸胃病學
  • 其他

第10章市場分析/預測:按生態系統

  • 概述
  • 應用科學
    • 基因組學
    • 藥物基因組學
    • 其他
  • 精確診斷
    • 分子診斷(MDx)
    • 醫學圖像處理
  • 數字健康/IT
    • 臨床決策支持系統(CDSS)
    • 大數據分析
    • IT基礎架構
    • 基因組學信息學
    • Insilico信息學
    • 移動健康
  • 精密處理
    • 臨床試驗
    • 細胞療法
    • 藥物發現/研究
    • 基因療法

第11章市場分析/預測:按地區/主要國家/地區

  • 概述
  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 法國
    • 意大利
    • 英國
    • 西班牙
    • 其他
  • 亞太地區
    • 中國
    • 日本
    • 澳大利亞
    • 印度
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 其他地區

第12章公司簡介

  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • Almac Group Ltd.
  • Astra Zeneca
  • ASURAGEN INC.
  • BGI Group
  • Bio-Rad Laboratories, Inc.
  • bioMerieux S.A.
  • Bristol-Myers Squibb Company
  • Danaher Corporation
  • F. Hoffmann-La Roche Ltd
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Invitae Corporation
  • Illumina, Inc.
  • Konica Minolta, Inc.
  • Laboratory Corporation of America Holdings
  • OPKO Health, Inc.
  • Partek, Inc.
  • Quest Diagnostics
  • QIAGEN N.V.*
  • Randox Laboratories Ltd.
  • Sanofi S.A.
  • Teva Pharmaceuticals Industries Ltd.
  • Thermo Fisher Scientific Inc.
目錄
Product Code: BHP0958SA

"Global Non-Oncology Precision Medicine Market to Reach $129.96 Billion by 2030."

Market Report Coverage - Non-Oncology Precision Medicine

Market Segmentation

  • By Application: Infectious Diseases, Neurology, Cardiovascular, Lifestyle and Endocrinology, Gastroenterology, Other Applications
  • By Ecosystem: Applied Sciences, Precision Diagnostics, Digital Health and Information Technology, Precision Therapeutics
  • By Region: North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World

Regional Segmentation

  • North America - U.S., Canada
  • Europe - Germany, France, Italy, U.K., Spain, Rest-of-Europe
  • Asia-Pacific - China, Japan, Australia, India, Rest-of-Asia-Pacific
  • Latin America - Brazil, Mexico, Rest-of-LATAM
  • Rest-of-the-World

Growth Drivers

  • Improved availability of targeted therapies and decreasing trial and error-based prescription
  • Reduced chances of adverse drug reactions
  • Decreasing overall cost of genome sequencing
  • Rising prevalence of chronic diseases

Market Challenges

  • Unclear regulatory framework and reimbursement scenario for personalized medicine
  • Limited knowledge about molecular mechanism/interaction
  • Integrating and securing Electronic Health Record

Market Opportunities

  • Research alliance across industry and academia would accelerate the market entry
  • Strong product pipeline and increasing FDA approvals

Key Non-Oncology Precision Medicine Companies Profiled

Abbott Laboratories, Agilent Technologies, Inc., Asuragen, Inc., Almac Group, AstraZeneca PLC, Bristol Myers Squibb, bioMerieux SA., BGI, Bio-Rad Laboratories, Inc F. Hoffmann-La Roche AG, Danaher Corp., GlaxoSmithKline plc., Gilead Sciences, Inc. Illumina, Inc., Invitae Corporation, Opko Health, Inc., Laboratory Corporation of America Holdings, Pacific Biosciences of California, Inc., Partek Incorporated, Randox Laboratories Ltd., Teva Pharmaceutical Industries Ltd., Thermofisher Scientific, QIAGEN, and Quest Diagnostics

Key Questions Answered in this Report:

  • What are the various types of technologies available in the non-oncology precision medicine market, and what are the benefits offered by them?
  • What are the key development strategies implemented by the key players to stand out in this market?
  • What are the emerging technologies that can take over the current technologies for molecular diagnosis within the non-oncology precision medicine market?
  • How have the strategic collaborations among the key players and academia provided a push to product development within the non-oncology precision medicine market?
  • Which technology has witnessed maximum adoption in terms of patent filing and development of molecular therapeutics within the market, and why?
  • What are the regulations pertaining to the global non-oncology precision medicine market in different regions?
  • What are the initiatives implemented by different government bodies regulating the development and commercialization of non-oncology precision medicine products and associated platforms?
  • How has COVID-19 impacted the non-oncology precision medicine market?
  • How will the urgency of the pandemic influence the global non-oncology precision medicine market?
  • What are the leading companies dominating the global non-oncology precision medicine market?
  • What are the significant research and developmental investments performed by the key market players?
  • What is the reimbursement scenario of the products offered in the global non-oncology precision medicine market?
  • Based on the application area, which global non-oncology precision medicine market application area is anticipated to witness a massive rise in demand in the forecast period?
  • How is each segment of the global non-oncology precision medicine market expected to grow during the forecast period, and what is the revenue expected to be generated by each of the segments by the end of 2030?

Market Overview

The precision medicine approach is used for several disease management, such as oncology, immunology, neurology, and infectious diseases. In the non-oncology precision medicine market, the application of molecular biology is for studying the cause of a patient's disease at the molecular level for diseases other than cancer, so that target-based therapies or individualized therapies can be applied to cure the patient's health-related problems.

The global non-oncology precision medicine market was valued at $41.1 in 2019, and it is expected to grow at an impressive double-digit rate of 11.03% and reach a value of $129.96 in 2030.

The existing non-oncology precision medicine market is favored by multiple factors, which include rising government initiatives, coupled up with the general population's growing awareness pertaining to molecular level diagnosis and treatment. Additionally, the increasing number of advancements in molecular diagnostics, more key players interested in investing for the development of novel personalized therapies, and increasing FDA approvals for such drugs among others.

Within the research report, the market is segmented on the basis of application (infectious diseases, neurology, cardiovascular, lifestyle and endocrinology, gastroenterology, other applications), ecosystem type (applied sciences, precision diagnostics, digital health and information technology, precision therapeutics), and region (North America, Europe, Asia Pacific, Latin America, and Rest-of-the-World). This segmentation highlights value propositions and business models useful for industry leaders and stakeholders. The research also comprises country-level analysis, go-to-market strategies of leading players, future opportunities, among others, to detail the scope and provide a 360-coverage of the domain.

Competitive Landscape

The non-oncology precision medicine market witnessed 59 collaborations and partnerships, four fundings and investments, 44 product launches and enhancements,26 regulatory and legal activities,18 mergers and acquisitions, and six business expansions during the period January 2016-August 2020.

Major players within the non-oncology precision medicine market are Abbott Laboratories, Agilent Technologies, Inc., Asuragen, Inc., Almac Group, AstraZeneca PLC, Bristol Myers Squibb, bioMerieux SA., BGI, Bio-Rad Laboratories, Inc F. Hoffmann-La Roche AG, Danaher Corp., GlaxoSmithKline plc., Gilead Sciences, Inc. Illumina, Inc., Invitae Corporation, Opko Health, Inc., Laboratory Corporation of America Holdings, Pacific Biosciences of California, Inc., Partek Incorporated, Randox Laboratories Ltd., Teva Pharmaceutical Industries Ltd., Thermofisher Scientific, QIAGEN, and Quest Diagnostics.

Table of Contents

Executive Summary

1 Product Definition

  • 1.1 Inclusion and Exclusion

2 Scope of the Research Study

  • 2.1 Research Scope

3 Research Methodology

  • 3.1 Primary Data Sources
  • 3.2 Secondary Data Sources
  • 3.3 Market Estimation Model
  • 3.4 Selection Criteria for Company Profiles

4 Market Overview

  • 4.1 Introduction
  • 4.2 Enabling Technologies of Precision Medicine Emphasizing Focus on Prevention
  • 4.3 Promising Potential and Role of Precision Medicine

5 Impact of COVID-19 Pandemic on Global Non-Oncology Precision Medicine Market

  • 5.1 Unprecedented Demand for Non-Oncology Precision Medicine Due to COVID-19
  • 5.2 COVID-19 Affecting Supply Chain of Non-Oncology Precision Medicine-Based Therapies
  • 5.3 Measures Taken to Address Current Problem

6 Global Non-Oncology Precision Medicine Market: Industry Analysis

  • 6.1 Legal and Regulatory Framework and Requirements
    • 6.1.1 North America
      • 6.1.1.1 Regulatory Requirements in U.S.
    • 6.1.2 Europe
    • 6.1.3 Asia-Pacific
  • 6.2 Patent Landscape

7 Global Non-Oncology Precision Medicine Market: Market Dynamics

  • 7.1 Overview
  • 7.2 Market Driving Factors
    • 7.2.1 Improved Availability of Targeted Therapies and Decreasing Trial and Error-Based Prescription
    • 7.2.2 Reduced Chances of Adverse Drug Reactions
    • 7.2.3 Decreasing Overall Cost of Genome Sequencing
    • 7.2.4 Rising Prevalence of Chronic Diseases
  • 7.3 Market Restraining Factors
    • 7.3.1 Unclear Regulatory Framework and Reimbursement Scenario for Personalized Medicine
    • 7.3.2 Limited Knowledge About Molecular Mechanism/Interaction
    • 7.3.3 Integrating and Securing Electronic Health Records
  • 7.4 Market Opportunities
    • 7.4.1 Research Alliance Across Industry and Academia Accelerating Market Entry
    • 7.4.2 Strong Pipeline and Increasing FDA Approvals

8 Global Non-Oncology Precision Medicine Market: Competitive Landscape

  • 8.1 Key Strategies and Developments
    • 8.1.1 Product Offerings
    • 8.1.2 Partnerships and Alliances
    • 8.1.3 Regulatory and Legal
    • 8.1.4 Mergers and Acquisitions
    • 8.1.5 Funding and Investments
  • 8.2 Market Share Analysis
  • 8.3 Growth-Share Analysis (by Company), 2019

9 Global Non-Oncology Precision Medicine Market (by Application), $Billion, 2019-2030

  • 9.1 Overview
  • 9.2 Infectious Diseases
    • 9.2.1 Respiratory Infections
    • 9.2.2 Gastrointestinal Infections
    • 9.2.3 Sexually Transmitted Infections
    • 9.2.4 Others
  • 9.3 Neurology/Physiatry
    • 9.3.1 Neurodegenerative Disorders
    • 9.3.2 Neuropsychiatric Disorders
    • 9.3.3 Others
  • 9.4 Lifestyle and Endocrinology
  • 9.5 Cardiovascular
    • 9.5.1 Cardiac Myopathies and Arrhythmia
    • 9.5.2 Others
  • 9.6 Gastroenterology
  • 9.7 Other Applications

10 Global Non-Oncology Precision Medicine Market (by Ecosystem), $Billion, 2019-2030

  • 10.1 Overview
  • 10.2 Applied Sciences
    • 10.2.1 Genomics
    • 10.2.2 Global Non-Oncology Precision Medicine Genomics Market (by Technology)
      • 10.2.2.1 Polymerase Chain Reaction (PCR)
      • 10.2.2.2 Precision Medicine Next-Generation Sequencing (PM NGS)
      • 10.2.2.3 Genome Editing
      • 10.2.2.4 Other Technologies
    • 10.2.3 Pharmacogenomics
    • 10.2.4 Other Applied Sciences
  • 10.3 Precision Diagnostics
    • 10.3.1 Molecular Diagnostics (MDx)
    • 10.3.2 Medical Imaging
  • 10.4 Digital Health and Information Technology
    • 10.4.1 Clinical Decision Support Systems (CDSS)
    • 10.4.2 Big Data Analytics
    • 10.4.3 IT Infrastructure
    • 10.4.4 Genomics Informatics
    • 10.4.5 In-Silico Informatics
    • 10.4.6 Mobile Health
  • 10.5 Precision Therapeutics
    • 10.5.1 Clinical Trials
    • 10.5.2 Cell Therapy
    • 10.5.3 Drug Discovery and Research
    • 10.5.4 Gene Therapy

11 Global Non-Oncology Precision Medicine Market (by Region), $Billion, 2019-2030

  • 11.1 Overview
  • 11.2 North America
    • 11.2.1 U.S.
    • 11.2.2 Canada
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 France
    • 11.3.3 Italy
    • 11.3.4 U.K.
    • 11.3.5 Spain
    • 11.3.6 Rest-of-Europe
  • 11.4 Asia-Pacific (APAC)
    • 11.4.1 China
    • 11.4.2 Japan
    • 11.4.3 Australia
    • 11.4.4 India
    • 11.4.5 Rest-of-Asia-Pacific
  • 11.5 Latin America
    • 11.5.1 Brazil
    • 11.5.2 Mexico
    • 11.5.3 Rest-of-LATAM
  • 11.6 Rest-of-the-World
    • 11.6.1 Rest-of-the-World Non-Oncology Precision Medicine Market Dynamics

12 Company Profiles

  • 12.1 Abbott Laboratories
    • 12.1.1 Company Overview
    • 12.1.2 Role of Abbott Laboratories in Global Non-Oncology Precision Medicine Market
    • 12.1.3 Financials
    • 12.1.4 SWOT Analysis
  • 12.2 Agilent Technologies, Inc.
    • 12.2.1 Company Overview
    • 12.2.2 Role of Agilent Technologies, Inc. in Global Non-Oncology Precision Medicine Market
    • 12.2.3 Financials
    • 12.2.4 SWOT Analysis
  • 12.3 Almac Group Ltd.
    • 12.3.1 Company Overview
    • 12.3.2 Role of Almac Group Ltd. in Global Non-Oncology Precision Medicine Market
    • 12.3.3 SWOT Analysis
  • 12.4 Astra Zeneca
    • 12.4.1 Company Overview
    • 12.4.2 Role of Astra Zeneca in Global Non-Oncology Precision Medicine Market
    • 12.4.3 Financials
    • 12.4.4 SWOT Analysis
  • 12.5 ASURAGEN INC.
    • 12.5.1 Company Overview
    • 12.5.2 Role of ASURAGEN Inc. in Global Non-Oncology Precision Medicine Market
    • 12.5.3 SWOT Analysis
  • 12.6 BGI Group
    • 12.6.1 Company Overview
    • 12.6.2 Role of BGI Group in Global Non-Oncology Precision Medicine Market
    • 12.6.3 SWOT Analysis
  • 12.7 Bio-Rad Laboratories, Inc.
    • 12.7.1 Company Overview
    • 12.7.2 Role of Bio-Rad Laboratories, Inc.in Global Non-Oncology Precision Medicine Market
    • 12.7.3 Financials
    • 12.7.4 SWOT Analysis
  • 12.8 bioMerieux S.A.
    • 12.8.1 Company Overview
    • 12.8.2 Role of bioMerieux SA. in Global Non-Oncology Precision Medicine Market
    • 12.8.3 Financials
    • 12.8.4 SWOT Analysis
  • 12.9 Bristol-Myers Squibb Company
    • 12.9.1 Company Overview
    • 12.9.2 Role of Bristol-Myers Squibb Company in Global Non-Oncology Precision Medicine Market
    • 12.9.3 Financials
    • 12.9.4 SWOT Analysis
  • 12.1 Danaher Corporation
    • 12.10.1 Company Overview
    • 12.10.2 Role of Danaher Corporation in Global Non-Oncology Precision Medicine Market
    • 12.10.3 Financials
    • 12.10.4 SWOT Analysis
  • 12.11 F. Hoffmann-La Roche Ltd
    • 12.11.1 Company Overview
    • 12.11.2 Role of F. Hoffman-LA Roche Ltd in Global Non-Oncology Precision Medicine Market
    • 12.11.3 Financials
    • 12.11.4 SWOT Analysis
  • 12.12 Gilead Sciences, Inc.
    • 12.12.1 Company Overview
    • 12.12.2 Role of Gilead Sciences, Inc. in Global Non-Oncology Precision Medicine Market
    • 12.12.3 Financials
    • 12.12.4 SWOT Analysis
  • 12.13 GlaxoSmithKline plc
    • 12.13.1 Company Overview
    • 12.13.2 Role of GlaxoSmithKline Plc in Global Non-Oncology Precision Medicine Market
    • 12.13.3 Financials
    • 12.13.4 SWOT Analysis
  • 12.14 Invitae Corporation
    • 12.14.1 Company Overview
    • 12.14.2 Role of Invitae Corporation in Global Non-Oncology Precision Medicine Market
    • 12.14.3 Financials
    • 12.14.4 SWOT Analysis
  • 12.15 Illumina, Inc.
    • 12.15.1 Company Overview
    • 12.15.2 Role of Illumina, Inc. in Global Non-Oncology Precision Medicine Market
    • 12.15.3 Financials
    • 12.15.4 SWOT Analysis
  • 12.16 Konica Minolta, Inc.
    • 12.16.1 Company Overview
    • 12.16.2 Role of Konica Minolta, Inc. in Global Non-Oncology Precision Medicine Market
    • 12.16.3 Financials
    • 12.16.4 SWOT Analysis
  • 12.17 Laboratory Corporation of America Holdings
    • 12.17.1 Company Overview
    • 12.17.2 Role of Laboratory Corporation of America Holdings in Global Non-Oncology Precision Medicine Market
    • 12.17.3 Financials
    • 12.17.4 SWOT Analysis
  • 12.18 OPKO Health, Inc.
    • 12.18.1 Company Overview
    • 12.18.2 Role of OPKO Health, Inc. in Global Non-Oncology Precision Medicine Market
    • 12.18.3 Financials
    • 12.18.4 SWOT Analysis
  • 12.19 Partek, Inc.
    • 12.19.1 Company Overview
    • 12.19.2 Role Partek, Inc. in Global Non-Oncology Precision Medicine Market
    • 12.19.3 SWOT Analysis
  • 12.2 Quest Diagnostics
    • 12.20.1 Company Overview
    • 12.20.2 Role of Quest Diagnostics in Global Non-Oncology Precision Medicine Market
    • 12.20.3 Financials
    • 12.20.4 SWOT Analysis
  • 12.21 QIAGEN N.V.*
    • 12.21.1 Company Overview
    • 12.21.2 Role of QIAGEN N.V. in Global Non-Oncology Precision Medicine Market
    • 12.21.3 Financials
    • 12.21.4 SWOT Analysis
  • 12.22 Randox Laboratories Ltd.
    • 12.22.1 Company Overview
    • 12.22.2 Role of Randox Laboratories Ltd. in Global Non-Oncology Precision Medicine Market
    • 12.22.3 SWOT Analysis
  • 12.23 Sanofi S.A.
    • 12.23.1 Company Overview
    • 12.23.2 Role of Sanofi SA in Global Non-Oncology Precision Medicine Market
    • 12.23.3 Financials
    • 12.23.4 SWOT Analysis
  • 12.24 Teva Pharmaceuticals Industries Ltd.
    • 12.24.1 Company Overview
    • 12.24.2 Role of Teva Pharmaceuticals Industries Ltd. in Global Non-Oncology Precision Medicine Market
    • 12.24.3 Financials
    • 12.24.4 SWOT Analysis
  • 12.25 Thermo Fisher Scientific Inc.
    • 12.25.1 Company Overview
    • 12.25.2 Role of Thermo Fisher Scientific Inc. in Global Non-Oncology Precision Medicine Market
    • 12.25.3 Financials
    • 12.25.4 SWOT Analysis

List of Tables

  • Table 4.1: Successful Non-Oncology Precision Medicine Interventions
  • Table 7.1: Percentage of Total Regional Aged Population (65 Years and Above: 2015 and 2030)
  • Table 9.1: FDA Approved Personalized Drugs Launched, Infectious Diseases, 2015-2019
  • Table 9.2: FDA Approved Personalized Drugs Launched, Neurology, 2015-2019
  • Table 9.3: FDA Approved Personalized Drugs Launched, Cardiology, 2015-2019
  • Table 9.4: FDA Approved Personalized Drugs Launched, Gastroenterology, 2015-2019
  • Table 9.5: FDA Approved Personalized Drugs Launched, Other Diseases, 2015-2019

List of Figures

  • Figure 1: Share of FDA Approved Non-Oncology Precision Medicine Drugs (2016-2018)
  • Figure 2: Global Non-Oncology Precision Medicine Market, 2019-2030
  • Figure 3: Market Drivers, Opportunities, and Restraints
  • Figure 4: Share of Key Developments and Strategies, by Company (January 2016-August 2020)
  • Figure 5: Growth-Share Matrix for Global Non-Oncology Precision Medicine Market (by Company), 2019
  • Figure 6: Global Non-Oncology Precision Medicine Applications Market Share (Application Type), 2019-2030
  • Figure 7: Global Non-Oncology Precision Medicine Market (by Region)
  • Figure 2.1: Global Non-Oncology Precision Medicine Market Segmentation
  • Figure 3.1: Global Non-Oncology Precision Medicine Market Research Methodology
  • Figure 3.2: Primary Research Methodology
  • Figure 3.3: Bottom-Up Approach (Segment-Wise Analysis)
  • Figure 3.4: Share of Total Number of Companies Profiled
  • Figure 4.1: Precision Medicine Model
  • Figure 4.2: Global Non-Oncology Precision Medicine Market, 2019-2030
  • Figure 4.3: Enabling Technologies of Precision Medicine
  • Figure 4.4: Potential of Precision Medicine
  • Figure 5.1: Pre-COVID-19 and Post-COVID-19 Scenario of Global Non-Oncology Precision Medicine Market, 2017-2025
  • Figure 5.2: Supply Chain of Non-Oncology Precision Medicine
  • Figure 5.3: Key Factors of Supply Chain
  • Figure 5.4: Measures to Bridge the Supply-Chain Gap in Non-Oncology Precision Medicine Market
  • Figure 6.1: Share of Patents Assigned (2015-2019)
  • Figure 6.2: Total Number of Patents Assigned to Key Technologies, 2016-2018
  • Figure 7.1: Impact Analysis of Market Dynamics
  • Figure 7.2: Percentage of Patients With Experience of Ineffective Drug Treatment
  • Figure 7.3: Steady Increase in Usage of Personalized Medicine
  • Figure 8.1: Share of Key Developments and Strategies, January 2016-August 2020
  • Figure 8.2: Share of Product Offerings, January 2016-August 2020
  • Figure 8.3: Share of Partnerships and Alliances, January 2016-August 2020
  • Figure 8.4: Share of Funding and Investment, January 2016-August 2020
  • Figure 8.5: Share of Mergers and Acquisitions, January 2016-August 2020
  • Figure 8.6: Share of Funding and Investments, January 2016-August 2020
  • Figure 8.7: Market Share Analysis: Global Non-Oncology Precision Medicine Market, 2019
  • Figure 8.8: Growth-Share Matrix for Global Non-Oncology Precision Medicine Market (by Company), 2019
  • Figure 9.1: Global Non-Oncology Precision Medicine Applications Market Share (Application Type), 2019-2030
  • Figure 9.2: Global Non-Oncology Precision Medicine Infectious Diseases Market, 2019-2030
  • Figure 9.3: Global on-Oncology Precision Medicine Market (for Respiratory Infections), 2019-2030
  • Figure 9.4: Global on-Oncology Precision Medicine Market (for Gastrointestinal Infections), 2019-2030
  • Figure 9.5: Global on-Oncology Precision Medicine Market (by Sexually Transmitted Infections), 2019-2030
  • Figure 9.6: Global on-Oncology Precision Medicine Market (for Other Infections), 2019-2030
  • Figure 9.7: Global Non-Oncology Precision Medicine Neurology Market, 2019-2030
  • Figure 9.8: Global on-Oncology Precision Medicine Market (for Neurodegenerative Disorders), 2019-2030
  • Figure 9.9: Global on-Oncology Precision Medicine Market (for Neuropsychiatric Disorders), 2019-2030
  • Figure 9.10: Global Non-Oncology Precision Medicine Market (for Other Neurology Disorders), 2019-2030
  • Figure 9.11: Global Non-Oncology Precision Medicine Lifestyle and Endocrinology Market, 2019-2030
  • Figure 9.12: Global Non-Oncology Precision Medicine Cardiovascular Market, 2019-2030
  • Figure 9.13: Global on-Oncology Precision Medicine Market (for Cardiac Myopathies and Arrhythmia), 2019-2030
  • Figure 9.14: Global Oncology Precision Medicine Market (by Other Cardiovascular Disorder), 2019-2030
  • Figure 9.15: Global Non-Oncology Precision Medicine Gastroenterology Market, 2019-2030
  • Figure 9.16: Global Non-Oncology Precision Medicine Other Applications Market, 2019-2030
  • Figure 10.1: Global Non-Oncology Precision Medicine Market (by Applied Sciences), 2019-2030
  • Figure 10.2: Global Non-Oncology Precision Medicine Applied Sciences Market Share (by Type), 2019-2030
  • Figure 10.3: Global Non-Oncology Precision Medicine Genomics Market, 2019-2030
  • Figure 10.4: Global Non-Oncology Precision Medicine Genomics Market Share (by Technology)
  • Figure 10.5: Global Non-Oncology Precision Medicine PCR Market, 2019-2030
  • Figure 10.6: Global Non-Oncology Precision Medicine NGS Market, 2019-2030
  • Figure 10.7: Global Non-Oncology Precision Medicine Genome Editing Market, 2019-2030
  • Figure 10.8: Global Non-Oncology Precision Medicine Other Technologies Market, 2019-2030
  • Figure 10.9: Global Non-Oncology Precision Medicine Pharmacogenomics Market, 2019-2030
  • Figure 10.10: Global Non-Oncology Precision Medicine Other Applied Sciences Market, 2019-2030
  • Figure 10.11: Global Non-Oncology Precision Medicine Market (by Precision Diagnostics)
  • Figure 10.12: Global Non-Oncology Precision Medicine Market (by Precision Diagnostics), 2019-2030
  • Figure 10.13: Global Non-Oncology Precision Medicine Diagnostics Market Share (by Type), 2019-2030
  • Figure 10.14: Global Non-Oncology Precision Medicine Molecular Diagnostics Market, 2019-2030
  • Figure 10.15: Global Non-Oncology Precision Medicine Medical Imaging Market, 2019-2030
  • Figure 10.16: Global Non-Oncology Precision Medicine Digital Health and Information Technology Market,2019-2030
  • Figure 10.17: Global Non-Oncology Precision Medicine Digital Health and Information Technology Market Share (by Type), 2019-2030
  • Figure 10.18: Global Non-Oncology Precision Medicine CDSS Market, 2019-2030
  • Figure 10.19: Global Non-Oncology Precision Medicine Big Data Analytics Market, 2019-2030
  • Figure 10.20: Global Non-Oncology Precision Medicine IT Infrastructure Market, 2019-2030
  • Figure 10.21: Global Non-Oncology Precision Medicine Genomics Informatics Market, 2019-2030
  • Figure 10.22: Global Non-Oncology Precision Medicine In-Silico Informatics Market, 2019-2030
  • Figure 10.23: Global Non-Oncology Precision Medicine Mobile Health Market, 2019-2030
  • Figure 10.24: Global Non-Oncology Precision Medicine Therapeutics Market, 2019-2030
  • Figure 10.25: Global Non-Oncology Precision Medicine Therapeutics Market Share (by Type), 2019-2030
  • Figure 10.26: Global Non-Oncology Precision Medicine Clinical Trials Market, 2019-2030
  • Figure 10.27: Global Non-Oncology Precision Medicine Cell Therapy Market, 2019-2030
  • Figure 10.28: Global Non-Oncology Precision Medicine Drug Discovery and Research Market, 2019-2030
  • Figure 10.29: Global Non-Oncology Precision Medicine Gene Therapy Market, 2019-2030
  • Figure 11.1: Global Non-Oncology Precision Medicine Market (by Region)
  • Figure 11.2: North America Global Non-Oncology Precision Medicine Market, 2019-2030
  • Figure 11.3: North America: Market Dynamics
  • Figure 11.4: North America Global Non-Oncology Precision Medicine Market (by Country), 2019-2030
  • Figure 11.5: U.S. Non-Oncology Precision Medicine Market, 2019-2030
  • Figure 11.6: Canada Non-Oncology Precision Medicine Market, 2019-2030
  • Figure 11.7: Europe Non-Oncology Precision Medicine Market, 2019-2030
  • Figure 11.8: Europe: Market Dynamics
  • Figure 11.9: Europe Non-Oncology Precision Medicine Market (by Country), 2019-2030
  • Figure 11.10: Germany Non-Oncology Precision Medicine Market, 2019-2030
  • Figure 11.11: France Non-Oncology Precision Medicine Market, 2019-2030
  • Figure 11.12: Italy Non-Oncology Precision Medicine Market, 2019-2030
  • Figure 11.13: The U.K. Non-Oncology Precision Medicine Market, 2019-2030
  • Figure 11.14: Spain Non-Oncology Precision Medicine Market, 2019-2030
  • Figure 11.15: Rest-of-Europe Non-Oncology Precision Medicine Market, 2019-2030
  • Figure 11.16: Asia-Pacific Non-Oncology Precision Medicine Market, 2019-2030
  • Figure 11.17: Asia-Pacific: Market Dynamics
  • Figure 11.18: Asia-Pacific Non-Oncology Precision Medicine Market (by Country), 2019-2030
  • Figure 11.19: China Non-Oncology Precision Medicine Market, 2019-2030
  • Figure 11.20: Japan Non-Oncology Precision Medicine Market, 2019-2030
  • Figure 11.21: Australia Non-Oncology Precision Medicine Market, 2019-2030
  • Figure 11.22: India Non-Oncology Precision Medicine Market, 2019-2030
  • Figure 11.23: Rest-of-Asia-Pacific Non-Oncology Precision Medicine Market, 2019-2030
  • Figure 11.24: Latin America Non-Oncology Precision Medicine Market, 2019-2030
  • Figure 11.25: Latin America: Market Dynamics
  • Figure 11.26: Latin America Global Non-Oncology Precision Medicine Market (by Country), 2019 and 2030
  • Figure 11.27: Brazil Non-Oncology Precision Medicine Market, 2019-2030
  • Figure 11.28: Mexico Non-Oncology Precision Medicine Market, 2019-2030
  • Figure 11.29: Mexico Non-Oncology Precision Medicine Market, 2019-2030
  • Figure 11.30: Rest-of-the-World Non-Oncology Precision Medicine Market, 2019-2030
  • Figure 12.1: Abbott Laboratories.: Overall Product Offerings
  • Figure 12.2: Abbott Laboratories: Overall Financials, 2017-2019
  • Figure 12.3: Abbott Laboratories: Net Revenue (by Business Segment), 2017-2019
  • Figure 12.4: Abbott Laboratories: Net Revenue (by Region), 2017-2019
  • Figure 12.5: Abbott Laboratories: Research and Development Expense, 2017-2019
  • Figure 12.6: Abbott Laboratories: SWOT Analysis
  • Figure 12.7: Agilent Technologies, Inc.: Overall Product Offerings
  • Figure 12.8: Agilent Technologies, Inc.: Overall Financials, 2017-2019
  • Figure 12.9: Agilent Technologies, Inc.: Net Revenue (by Business Segment), 2017-2019
  • Figure 12.10: Agilent Technologies, Inc.: Revenue (by Region), 2017-2019
  • Figure 12.11: Agilent Technologies, Inc.: Research and Development Expense, 2017-2019
  • Figure 12.12: Agilent Technologies, Inc.: SWOT Analysis
  • Figure 12.13: Almac Group Ltd.: Overall Product Offerings
  • Figure 12.14: Almac Group Ltd.: SWOT Analysis
  • Figure 12.15: Astra Zeneca: Overall Product Portfolio
  • Figure 12.16: Astra Zeneca: Overall Financials, 2017-2019
  • Figure 12.17: Astra Zeneca: Revenue (by Business Segment), 2017-2019
  • Figure 12.18: Astra Zeneca: Revenue (by Region), 2017-2019
  • Figure 12.19: Astra Zeneca: SWOT Analysis
  • Figure 12.20: ASURAGEN, INC.: Overall Product Offerings
  • Figure 12.21: ASURAGEN INC.: SWOT Analysis
  • Figure 12.22: BGI Group.: Overall Product Portfolio
  • Figure 12.23: BGI Group: SWOT Analysis
  • Figure 12.24: Bio-Rad Laboratories, Inc: Overall Product Offerings
  • Figure 12.25: Bio-Rad Laboratories, Inc: Overall Financials, 2017-2019
  • Figure 12.26: Bio-Rad Laboratories, Inc: Revenue (by Business Segment), 2017-2019
  • Figure 12.27: Bio-Rad Laboratories, Inc: Revenue (by Region), 2017-2019
  • Figure 12.28: Bio-Rad Laboratories, Inc. R&D Expenditure, 2017-2019
  • Figure 12.29: Bio-Rad Laboratories, Inc.: SWOT Analysis
  • Figure 12.30: bioMerieux S.A.: Overall Product Portfolio
  • Figure 12.31: bioMerieux S.A.: Overall Financials, 2017-2019
  • Figure 12.32: bioMerieux S.A.: Revenue (by Segment), 2017-2019
  • Figure 12.33: bioMerieux S.A.: Revenue (by Region), 2018 and 2019
  • Figure 12.34: bioMerieux S.A.: SWOT Analysis
  • Figure 12.35: Bristol-Myers Squibb Company: Overall Product Portfolio
  • Figure 12.36: Bristol-Myers Squibb Company: Overall Financials, 2017-2019
  • Figure 12.37: Bristol-Myers Squibb Company R&D Expenditure, 2017-2019
  • Figure 12.38: Bristol-Myers Squibb Company: SWOT Analysis
  • Figure 12.39: Danaher Corporation: Overall Product Portfolio
  • Figure 12.40: Danaher Corporation: Overall Financials, 2017-2019
  • Figure 12.41: Danaher Corporation: Revenue (by Business Segment), 2017-2019
  • Figure 12.42: Danaher Corporation: SWOT Analysis
  • Figure 12.43: F. Hoffmann-La Roche Ltd: Product Portfolio
  • Figure 12.44: F. Hoffmann-La Roche Ltd: Overall Financials, 2017-2019
  • Figure 12.45: F. Hoffmann-La Roche Ltd: Revenue (by Segment), 2017-2019
  • Figure 12.46: Hoffmann-La Roche Ltd: Revenue (by Region), 2017-2019
  • Figure 12.47: F. Hoffmann-La Roche Ltd: R&D Expenditure, 2017-2019
  • Figure 12.48: F. Hoffmann-La Roche Ltd: SWOT Analysis
  • Figure 12.49: Gilead Sciences, Inc.: Overall Product Portfolio
  • Figure 12.50: Gilead Sciences, Inc.: Overall Financials, 2017-2019
  • Figure 12.51: Gilead Sciences, Inc. : R&D Expenditure, 2017-2019
  • Figure 12.52: Gilead Science, Inc.: SWOT Analysis
  • Figure 12.53: GlaxoSmithKline Plc.: Overall Product Portfolio
  • Figure 12.54: GlaxoSmithKline plc: Overall Financials, 2017-2019
  • Figure 12.55: GlaxoSmithKline plc: Revenue (by Segment), 2017-2019
  • Figure 12.56: GlaxoSmithKline plc: Revenue (by Region), 2017-2019
  • Figure 12.57: GlaxoSmithKline plc: R&D Expenditure, 2017-2019
  • Figure 12.58: GlaxoSmithKline plc: SWOT Analysis
  • Figure 12.59: Invitae Corporation: Overall Product Portfolio
  • Figure 12.60: Invitae Corporation: Overall Financials, 2017-2019
  • Figure 12.61: Invitae Corporation: Revenue (by Segment), 2017-2019
  • Figure 12.62: Invitae Corporation: Revenue (by Region), 2017-2019
  • Figure 12.63: Invitae Corporation: R&D Expenditure, 2017-2019
  • Figure 12.64: Invitae Corporation: SWOT Analysis
  • Figure 12.65: Illumina, Inc.: Overall Product Portfolio
  • Figure 12.66: Illumina, Inc.: Overall Financials, 2017-2019
  • Figure 12.67: Illumina, Inc.: Revenue (by Segment), 2017-2019
  • Figure 12.68: Illumina, Inc.: Revenue (by Region), 2017-2019
  • Figure 12.69: Illumina, Inc.: R&D Expenditure, 2017-2019
  • Figure 12.70: Illumina, Inc.: SWOT Analysis
  • Figure 12.71: Konica Minolta, Inc.: Overall Product Portfolio
  • Figure 12.72: Konica Minolta, Inc.: Overall Financials, 2017-2019
  • Figure 12.73: Konica Minolta, Inc.: Revenue (by Region), 2017-2019
  • Figure 12.74: Konica Minolta, Inc.: Research and Development Expense, 2017-2019
  • Figure 12.75: Konica Minolta, Inc.: SWOT Analysis
  • Figure 12.76: Laboratory Corporation of America Holdings.: Overall Product Portfolio
  • Figure 12.77: Laboratory Corporation of America Holdings: Overall Financials, 2017-2019
  • Figure 12.78: Laboratory Corporation of America Holdings: Revenue (by Segment), 2017-2019
  • Figure 12.79: Laboratory Corporation of America Holdings: Revenue (by Region), 2019
  • Figure 12.80: Laboratory Corporation of America Holdings: SWOT Analysis
  • Figure 12.81: OPKO Health, Inc.: Overall Product Portfolio
  • Figure 12.82: OPKO Health, Inc.: Overall Financials, 2017-2019
  • Figure 12.83: OPKO Health, Inc: Net Revenue (by Business Segment), 2017-2019
  • Figure 12.84: OPKO Health, Inc.: Net Revenue (by Region), 2017-2019
  • Figure 12.85: OPKO Health, Inc.: Research and Development Expense, 2017-2019
  • Figure 12.86: OPKO Health, Inc.: SWOT Analysis
  • Figure 12.87: Partek, Inc: Overall Product Portfolio
  • Figure 12.88: Partek, Inc.: SWOT Analysis
  • Figure 12.89: Quest Diagnostics Incorporated: Overall Product Offerings
  • Figure 12.90: Quest Diagnostics Incorporated: Overall Financials, 2017-2019
  • Figure 12.91: Quest Diagnostics Incorporated: Revenue (by Business Segment), 2017-2019
  • Figure 12.92: Quest Diagnostics Incorporated: SWOT Analysis
  • Figure 12.93: QIAGEN N.V.: Overall Product Portfolio
  • Figure 12.94: QIAGEN N.V.: Overall Financials, 2017-2019
  • Figure 12.95: QIAGEN N.V.: Revenue (by Segment), 2017-2019
  • Figure 12.96: QIAGEN N.V.: Revenue (by Region), 2017-2019
  • Figure 12.97: QIAGEN N.V.: R&D Expenditure, 2017-2019
  • Figure 12.98: QIAGEN N.V.: SWOT Analysis
  • Figure 12.99: Randox Laboratories Ltd.: SWOT Analysis
  • Figure 12.100: Sanofi SA: Overall Product Portfolio
  • Figure 12.101: Sanofi SA: Overall Financials, 2017-2019
  • Figure 12.102: Sanofi SA: Revenue (by Segment), 2017-2019
  • Figure 12.103: Sanofi SA: Revenue (by Region), 2017-2019
  • Figure 12.104: Sanofi SA: R&D Expenditure, 2017-2019
  • Figure 12.105: Sanofi SA: SWOT Analysis
  • Figure 12.106: Teva Pharmaceuticals Industries Ltd.: Overall Product Portfolio
  • Figure 12.107: Teva Pharmaceuticals Industries Ltd.: Overall Financials, 2017-2019
  • Figure 12.108: Teva Pharmaceuticals Industries Ltd.: Revenue (by Region), 2017-2019
  • Figure 12.109: Teva Pharmaceuticals Industries Ltd. R&D Expenditure, 2017-2019
  • Figure 12.110: Teva Pharmaceuticals Industries Ltd.: SWOT Analysis
  • Figure 12.111: Thermo Fisher Scientific Inc.: Overall Product Portfolio
  • Figure 12.112: Thermo Fisher Scientific Inc.: Overall Financials, 2017-2019
  • Figure 12.113: Thermo Fisher Scientific Inc.: Revenue (by Segment), 2017-2019
  • Figure 12.114: Thermo Fisher Scientific Inc.: Revenue (by Region), 2017-2019
  • Figure 12.115: Thermo Fisher Scientific Inc.: R&D Expenditure, 2017-2019
  • Figure 12.116: Thermo Fisher Scientific Inc.: SWOT Analysis